Cellular and antibody responses directed against the HIV-1 principal neutralizing domain in HIV-1-infected children.

The principal neutralizing domain (PND) for antibody response is located within the V3 variable region of gp120 and can also stimulate T-cell responses. In some adults infected with human immunodeficiency virus (HIV) an HIV-1-specific T-cell response can be detected by demonstrating in vitro proliferation to HIV-1 proteins and peptides. In other HIV-1 infected adults an HIV-1-specific T-cell response can involve interleukin 2 (IL-2) secretion in the absence of T-cell proliferation. To elucidate the T-cell responses to PND in children, we examined the proliferative and the IL-2 secretory responses of peripheral blood lymphocytes from 19 HIV-1-infected children toward a peptide which contained a highly conserved sequence of the principal neutralizing domain of HIVMN (PND-MN). Stimulation with PND-MN induced proliferation of lymphocytes from 2 of the children and IL-2 secretion by lymphocytes from 5 of the children. In a 3-month-old infant, the in vitro cellular response to the PND-MN indicated HIV-1 infection prior to the detection p24 antigen in her serum. Although antibodies directed against PND-MN were detected in all but one of the children examined, the presence of high-affinity/avidity antibodies to the PND-MN correlated with the presence of a cellular response to PND-MN. Thus, in HIV-1-infected children an HIV-1 specific T-cell response in the absence of a proliferative response can be assessed by determination of the IL-2 secretory response and correlates with the generation of high-affinity/avidity antibodies.

[1]  A. Casadevall,et al.  Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans , 1992, The Lancet.

[2]  K. Cease,et al.  Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primates. , 1991, Journal of immunology.

[3]  A. Profy,et al.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 , 1990, Science.

[4]  J. Davide,et al.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. , 1990, Science.

[5]  J. Ambrus,et al.  Divergent activities of protein kinases in IL-6-induced differentiation of a human B cell line. , 1990, Journal of immunology.

[6]  A. Rubinstein,et al.  Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. Blattner,et al.  C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals. , 1990, AIDS research and human retroviruses.

[8]  J. Berzofsky,et al.  A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. , 1989, Science.

[9]  R. Laskov,et al.  The role of somatic hypermutation in the generation of antibody diversity. , 1989, Science.

[10]  J. Berzofsky,et al.  Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals , 1989, Nature.

[11]  K. Steimer,et al.  Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. , 1989, The Journal of clinical investigation.

[12]  D. Richman,et al.  T cell recognition of HIV synthetic peptides in a natural infection. , 1989, Journal of immunology.

[13]  K. Cease,et al.  Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans , 1988, Nature.

[14]  J. Blomberg,et al.  Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Debouck,et al.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Arthur,et al.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Margolick,et al.  Functional and biochemical characterization of B-cell differentiation factor (BCDF) produced by an HTLV-I-transformed human T-cell clone and demonstration of specific binding of the factor to a BCDF responsive cell line. , 1987, Cellular immunology.

[18]  R. M. Khaitov,et al.  Immunology of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. An update. , 1987, Annals of internal medicine.

[19]  R. Kurth,et al.  Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection , 1987, Journal of virology.

[20]  T. Waldmann,et al.  Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. , 1985, The New England journal of medicine.

[21]  A. Fauci,et al.  Characterization of a T4+/Leu-8+ T cell clone that directly helps B cell Ig production by secreting B cell differentiation factor. , 1985, Journal of immunology.

[22]  Kendall A. Smith,et al.  T cell growth factor: parameters of production and a quantitative microassay for activity. , 1978, Journal of immunology.

[23]  T. Merigan,et al.  Recombinant HIV structural proteins detect specific cellular immunity in vitro in infected individuals. , 1988, AIDS research and human retroviruses.

[24]  M. Borzy Interleukin 2 production and responsiveness in individuals with acquired immunodeficiency syndrome and the generalized lymphadenopathy syndrome. , 1987, Cellular immunology.